Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use

By sjmartinez • April 6, 2025

Karpouzas GA, Gonzalez-Gay MA, Corrales A, Myasoedova E, Rantapää-Dahlqvist S, Sfikakis PP, Dessein P, Hitchon C, Pascual-Ramos V, Contreras-Yáñez I, Colunga-Pedraza IJ, Galarza-Delgado DA, Azpiri-Lopez JR, Semb AG, van Riel PLCM, Misra DP, Patrick D, Bridal Logstrup B, Hauge EM, Kitas G, Ormseth SR; for An inTernationAl Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Influence of body mass index on cardiovascular risk in rheumatoid arthritis varies across anti-citrullinated protein antibody status and biologic use. RMD Open. 2025 Apr 5;11(2):e005464. doi: 10.1136/rmdopen-2025-005464. PMID: 40187772.

Tags: Anti-Citrullinated Protein Antibodies, Arthritis, biological therapy, cardiovascular diseases, Harbor UCLA, Publications, Rheumatoid, Rheumatology

Facilitators and challenges in the implementation of the Care Ecosystem at six clinical sites in the United States: A qualitative study

Sideman AB, Merrilees J, Dulaney S, Allawala M, Barclay M, Rosenbloom M, Hanson LR, Ward KT, Hess M, Olney NT, Lum HD, Sawyer RJ, Possin[...]

Berger disease redux

Glassock RJ. Berger disease redux. Kidney Int. 2025 Dec;108(6):999-1001. doi: 10.1016/j.kint.2025.09.021. PMID: 41271316.

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani[...]